Emergent BioSolutions’ (EBS) “Buy” Rating Reiterated at Rodman & Renshaw

Rodman & Renshaw restated their buy rating on shares of Emergent BioSolutions (NYSE:EBS) in a research report released on Friday morning, Benzinga reports. They currently have a $16.00 target price on the biopharmaceutical company’s stock.

Separately, Benchmark reaffirmed a buy rating and set a $8.00 target price on shares of Emergent BioSolutions in a research note on Friday, August 16th.

Emergent BioSolutions Trading Up 3.1 %

Shares of EBS opened at $7.87 on Friday. The stock has a market capitalization of $416.40 million, a P/E ratio of -0.71 and a beta of 1.60. The firm has a fifty day simple moving average of $9.68 and a two-hundred day simple moving average of $6.08. The company has a quick ratio of 0.54, a current ratio of 1.06 and a debt-to-equity ratio of 1.16. Emergent BioSolutions has a twelve month low of $1.42 and a twelve month high of $15.10.

Emergent BioSolutions (NYSE:EBS) last released its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($2.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.97) by ($1.35). Emergent BioSolutions had a negative net margin of 53.26% and a negative return on equity of 34.38%. The business had revenue of $254.70 million for the quarter, compared to the consensus estimate of $199.47 million. During the same period in the previous year, the company earned ($1.06) EPS. On average, research analysts anticipate that Emergent BioSolutions will post -1.98 EPS for the current year.

Hedge Funds Weigh In On Emergent BioSolutions

A number of institutional investors have recently added to or reduced their stakes in EBS. Charles Schwab Investment Management Inc. grew its position in shares of Emergent BioSolutions by 84.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 2,873,984 shares of the biopharmaceutical company’s stock worth $6,898,000 after buying an additional 1,312,934 shares during the period. American Century Companies Inc. increased its stake in shares of Emergent BioSolutions by 240.9% during the second quarter. American Century Companies Inc. now owns 881,893 shares of the biopharmaceutical company’s stock valued at $6,015,000 after purchasing an additional 623,201 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Emergent BioSolutions by 14.7% during the first quarter. Vanguard Group Inc. now owns 3,411,549 shares of the biopharmaceutical company’s stock valued at $8,631,000 after purchasing an additional 436,911 shares during the last quarter. Federated Hermes Inc. increased its position in Emergent BioSolutions by 1,314.0% during the 2nd quarter. Federated Hermes Inc. now owns 273,287 shares of the biopharmaceutical company’s stock valued at $1,864,000 after buying an additional 253,960 shares in the last quarter. Finally, Marshall Wace LLP raised its stake in Emergent BioSolutions by 75.4% during the second quarter. Marshall Wace LLP now owns 542,813 shares of the biopharmaceutical company’s stock valued at $3,702,000 after buying an additional 233,341 shares during the last quarter. Institutional investors own 78.40% of the company’s stock.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.